Clinical Trial Detail

NCT ID NCT02576431
Title Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Loxo Oncology, Inc.
Indications

salivary gland cancer

biliary tract cancer

Advanced Solid Tumor

sarcoma

colorectal cancer

central nervous system cancer

non-small cell lung carcinoma

thyroid cancer

Therapies

Larotrectinib

Age Groups: adult

Additional content available in CKB BOOST